Services
Company
Legal and Governance
Publication Library / Publications
Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review
Introduction
Mucormycosis, hyalohyphomycosis, chromoblastomycosis, and fungal mycetoma are rare invasive fungal infections (IFIs) that cause significant morbidity and mortality in immunocompromised patients. Few effective treatment options are available for these IFIs.
Methods
We performed a systematic literature review of MEDLINE and Embase to identify studies published from 2005 (year of posaconazole approval) to October 22, 2022, reporting the efficacy/effectiveness of posaconazole monotherapy or combination therapy for treating mucormycosis, hyalohyphomycosis, chromoblastomycosis, and mycetoma. Positive outcomes or positive clinical outcomes were defined as reporting of a positive efficacy/effectiveness measure (i.e., no relapse, response, cure, radiological improvement, clinical / symptom improvement, or survived therapy).
Results
Of 3207 articles identified (after removing duplicates), 533 articles (mostly case reports) were included. Positive clinical outcomes with posaconazole therapy were observed in most patients with mucormycosis (74.8%, 1197/1601), hyalohyphomycosis (58.5%, 62/106), chromoblastomycosis (90.5%, 19/21), and mycetoma (100%, 5/5). Overall survival was around 70% or greater across the IFIs examined. Positive response was higher in second-line monotherapy than first-line monotherapy in mucormycosis and chromoblastomycosis. Higher mortality was observed with combination therapy than monotherapy in mucormycosis and hyalohyphomycosis infections (except for first-line use in mucormycosis). Positive clinical outcome was 78.6% and overall survival was 78.6% in 323 coronavirus disease (COVID)-associated mucormycosis infection cases.
Conclusion
Despite the rarity of these IFIs, substantial data have been published since posaconazole was initially approved in 2005, and the real-world case reports demonstrate that posaconazole is an effective therapeutic option alone or in combination for the treatment of these rare IFIs.
Authors
M Bernauer, H Waskin, N Cossrow, A Kaminski, A Simon, H Campbell, D Patel
Journal
International Journal of Antimicrobial Agents
Therapeutic Area
Infectious diseases and vaccines
Center of Excellence
Market Access Strategy
Year
2025
Read full article